Hyundai BioLand Co Ltd
KOSDAQ:052260
Intrinsic Value
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. [ Read More ]
The intrinsic value of one Hyundai BioLand Co Ltd stock under the Base Case scenario is 3 331.88 KRW. Compared to the current market price of 5 770 KRW, Hyundai BioLand Co Ltd is Overvalued by 42%.
Valuation Backtest
Hyundai BioLand Co Ltd
Run backtest to discover the historical profit from buying and selling Hyundai BioLand Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Hyundai BioLand Co Ltd
| Current Assets | 82B |
| Cash & Short-Term Investments | 21.7B |
| Receivables | 16.6B |
| Other Current Assets | 43.7B |
| Non-Current Assets | 104B |
| Long-Term Investments | 824.4m |
| PP&E | 77.9B |
| Intangibles | 12.2B |
| Other Non-Current Assets | 13B |
| Current Liabilities | 46.6B |
| Accounts Payable | 3.9B |
| Accrued Liabilities | 2.1B |
| Short-Term Debt | 26.8B |
| Other Current Liabilities | 13.8B |
| Non-Current Liabilities | 1.1B |
| Long-Term Debt | 282.9m |
| Other Non-Current Liabilities | 785.9m |
Earnings Waterfall
Hyundai BioLand Co Ltd
|
Revenue
|
105.5B
KRW
|
|
Cost of Revenue
|
-66.4B
KRW
|
|
Gross Profit
|
39.1B
KRW
|
|
Operating Expenses
|
-30B
KRW
|
|
Operating Income
|
9.1B
KRW
|
|
Other Expenses
|
-1.2B
KRW
|
|
Net Income
|
7.9B
KRW
|
Free Cash Flow Analysis
Hyundai BioLand Co Ltd
| KRW | |
| Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Hyundai BioLand Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Hyundai BioLand Co Ltd's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Hyundai BioLand Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Hyundai BioLand Co Ltd's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Hyundai BioLand Co Ltd
According to Wall Street analysts, the average 1-year price target for Hyundai BioLand Co Ltd is 24 000 KRW .
Shareholder Return
Price
Hyundai BioLand Co Ltd
| Average Annual Return | -0.65% |
| Standard Deviation of Annual Returns | 33.64% |
| Max Drawdown | -80% |
| Market Capitalization | 173.1B KRW |
| Shares Outstanding | 30 000 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
Contact
IPO
Employees
Officers
The intrinsic value of one Hyundai BioLand Co Ltd stock under the Base Case scenario is 3 331.88 KRW.
Compared to the current market price of 5 770 KRW, Hyundai BioLand Co Ltd is Overvalued by 42%.
You don't have any saved screeners yet
